Uncategorized

GSK abandons Alector after back-to-back neuro stumbles

Published

on

GSK and Alector first partnered in 2021 to advance two antibodies for neurodegenerative diseases. Both assets have since failed to show significant clinical benefit.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version